Clinical Trials on Primary Immunodeficiency Disorders

Total 186764 results

Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
BriovaRx Infusion Services
Bio Products Laboratory (BPL)

Completed

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Primary Immunodeficiency Disease (PIDD)

United States
Takeda

Recruiting

At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill

Primary Immunodeficiency Diseases (PID)

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)

United States
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire

Completed

Immune Globulin Subcutaenous (Human), 20%

Primary Immunodeficiency Diseases (PID)

Germany, Austria, Hungary, Sweden, United Kingdom
University Hospital, Montpellier

Recruiting

Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care. (DIPREA)

Primary Immunodeficiency

France
Biotest
Syneos Health

Completed

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Primary Immunodeficiency Disease

United States, Germany, Hungary, Russian Federation, Spain
Grifols Therapeutics LLC

Withdrawn

Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States
Beijing Children's Hospital
Shenzhen Children's Hospital; Capital Institute of Pediatrics, China

Unknown

Pediatric Primary Immunodeficiency Disease (PID) in China

Primary Immunodeficiency Disease
Children's Hospital of Philadelphia
University of California, San Francisco

Recruiting

Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies

Immunodeficiencies | Immune Dysregulation Syndromes

United States
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire

Completed

A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

Denmark, United Kingdom, Czechia, France, Greece, Hungary, Slovakia, Sweden
Baxalta now part of Shire

Completed

Phase 2/3 Study of IGSC, 20% in PIDD

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)

Primary Immunodeficiency Diseases (PID)

Canada
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID); National Institute...

Completed

Participation in a Research Registry for Immune Disorders

CGD | Wiskott-Aldrich Syndrome | Primary Immunodeficiencies | APECED | SCID

United States
Great Ormond Street Hospital for Children NHS Foundation...

Unknown

Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)

X-linked Severe Combined Immunodeficiency

United Kingdom
Kedrion S.p.A.

Recruiting

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) (KIDCARES10)

Primary Immunodeficiency Disease

Italy, United States, Portugal, Hungary, Russian Federation, Slovakia
Kedrion S.p.A.

Completed

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients (CARES10)

Primary Immunodeficiency Disease

United States
Children's Hospital of Fudan University
The First Affiliated Hospital of Zhengzhou University; Shanghai Children's... and other collaborators

Active, not recruiting

Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID

Severe Combined Immunodeficiency Disease

China
National Human Genome Research Institute (NHGRI)

Completed

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency

Severe Combined Immunodeficiency Syndrome

United States
Great Ormond Street Hospital for Children NHS Foundation...

Recruiting

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

Severe Combined Immunodeficiency, X-Linked

United Kingdom
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

China
IRCCS San Raffaele
Fondazione Telethon

Completed

Gene Therapy for ADA-SCID

Severe Combined Immunodeficiency Syndrome
University of California, Los Angeles
Great Ormond Street Hospital for Children NHS Foundation Trust

Enrolling by invitation

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

Adenosine Deaminase Deficiency | Severe Combined Immunodeficiency (SCID)

United States, United Kingdom
National Institute of Allergy and Infectious Diseases...

Unknown

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency (LVXSCID-OC)

X-Linked Combined Immunodeficiency Diseases

United States
National Institute of Allergy and Infectious Diseases...

Completed

Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)

Severe Combined Immunodeficiency

United States
Nantes University Hospital

Completed

Generalized Neonatal Screening of Severe Combined Immunodeficiencies (DEPISTREC)

Severe Combined Immunodeficiency, Atypical

France
Children's Hospital of Fudan University

Recruiting

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

Activated PI3K-delta Syndrome | Immunodeficiency Primary

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Severe Combined Immunodeficiency | Adenosine Deaminase Deficiency | Immune System Disorder | Autosomal Recessive Disorder | Purine-Nucleoside Phosphorylase Deficiency | Severe Combined Immunodeficiency With Absence of T and B Cells | X-Linked Severe Combined Immunodeficiency

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)

United States
St. Jude Children's Research Hospital
National Heart, Lung, and Blood Institute (NHLBI); Assisi Foundation; California...

Suspended

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)

Severe Combined Immunodeficiency Disease, X-linked

United States
Assistance Publique - Hôpitaux de Paris

Completed

Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID2)

X-linked Severe Combined Immunodeficiency

France
Meyer Children's Hospital IRCCS

Active, not recruiting

Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.

Cytopenia

Italy, United States, Belgium
Leiden University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development; Horizon...

Recruiting

Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID (RAG1-SCID)

Severe Combined Immunodeficiency Due to RAG1 Deficiency

Spain, Netherlands, Italy, Poland, Australia, Turkey, United Kingdom
University of California, Los Angeles
Orchard Therapeutics; California Institute for Regenerative Medicine (CIRM)

Completed

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Severe Combined Immunodeficiency Due to ADA Deficiency

United States
Children's Hospital of Chongqing Medical University

Recruiting

Gene Therapy for X Linked Severe Combined Immunodeficiency

Gene Therapy

China
University Children's Hospital, Zurich
University Hospital, Geneva; University Children's Hospital Basel

Recruiting

Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies (GSI)

Immunologic Deficiency Syndromes

Switzerland
Prothya Biosolutions

Completed

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml (Nanogam)

Primary Immunodeficiency

Netherlands
Assistance Publique - Hôpitaux de Paris

Recruiting

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) (ARTEGENE)

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

France
Great Ormond Street Hospital for Children NHS Foundation...
Orchard Therapeutics

Completed

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Severe Combined Immunodeficiency Due to ADA Deficiency

United Kingdom
University of California, Los Angeles

Withdrawn

A Clinical Study to Enable Process Validation of Commercial Grade OTL-101

Severe Combined Immunodeficiency Due to ADA Deficiency

United States

Clinical Trials on Primary Immunodeficiency Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations